{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T04:13:03Z","timestamp":1793592783262,"version":"4.5.0"},"reference-count":149,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,6,28]],"date-time":"2025-06-28T00:00:00Z","timestamp":1751068800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,6,28]],"date-time":"2025-06-28T00:00:00Z","timestamp":1751068800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Inflammopharmacol"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1007\/s10787-025-01817-8","type":"journal-article","created":{"date-parts":[[2025,6,28]],"date-time":"2025-06-28T07:13:15Z","timestamp":1751094795000},"page":"3701-3723","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Targeting the double-edged sword: cytokines in the pathogenesis and treatment of autoimmune diseases"],"prefix":"10.1007","volume":"33","author":[{"given":"Fatima","family":"Dandash","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zahraa","family":"Salhab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rawan","family":"Issa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeinab","family":"Al Dirani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariam","family":"Hamze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel","family":"Fares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatima","family":"Berro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatima","family":"Shaalan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Hamade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makram","family":"Merimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehdi","family":"Najar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rayan","family":"Dakroub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douaa","family":"Khreis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8442-1619","authenticated-orcid":false,"given":"Mohammad","family":"Fayyad-Kazan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hussein","family":"Fayyad-Kazan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,28]]},"reference":[{"key":"1817_CR1","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1016\/S0140-6736(21)00676-0","volume":"397","author":"O Abani","year":"2021","unstructured":"Abani O, Abbas A, Abbas F, Abbas M, Abbasi S, Abbass H, Abbott A, Abdallah N, Abdelaziz A, Abdelfattah M (2021) Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet 397:1637\u20131645","journal-title":"Lancet"},{"key":"1817_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/ar2936","volume":"12","author":"IE Adamopoulos","year":"2010","unstructured":"Adamopoulos IE, Chao C-C, Geissler R, Laface D, Blumenschein W, Iwakura Y, McClanahan T, Bowman EP (2010) Interleukin-17A upregulates receptor activator of NF-\u03baB on osteoclast precursors. Arthrit Res Ther 12:1\u201311","journal-title":"Arthrit Res Ther"},{"key":"1817_CR3","doi-asserted-by":"publisher","first-page":"1307394","DOI":"10.3389\/fmed.2024.1307394","volume":"11","author":"I Aggeletopoulou","year":"2024","unstructured":"Aggeletopoulou I, Kalafateli M, Tsounis EP, Triantos C (2024) Exploring the role of IL-1\u03b2 in inflammatory bowel disease pathogenesis. Front Med 11:1307394","journal-title":"Front Med"},{"key":"1817_CR4","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1186\/s12974-024-03126-3","volume":"21","author":"G Arellano","year":"2024","unstructured":"Arellano G, Acu\u00f1a E, Loda E, Moore L, Tichauer JE, Castillo C, Vergara F, Burgos PI, Penaloza-Macmaster P, Miller SD (2024) Therapeutic role of interferon-\u03b3 in experimental autoimmune encephalomyelitis is mediated through a tolerogenic subset of splenic CD11b+ myeloid cells. J Neuroinflamm 21:144","journal-title":"J Neuroinflamm"},{"key":"1817_CR5","doi-asserted-by":"publisher","first-page":"121","DOI":"10.2165\/00063030-200418020-00005","volume":"18","author":"LM Bang","year":"2004","unstructured":"Bang LM, Keating GM (2004) Adalimumab: a review of its use in rheumatoid arthritis. BioDrugs 18:121\u2013139","journal-title":"BioDrugs"},{"key":"1817_CR6","unstructured":"Bank D (2021) Mavrilimumab. DrugBank"},{"key":"1817_CR7","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1097\/CCM.0b013e318211ff56","volume":"39","author":"T Barkhausen","year":"2011","unstructured":"Barkhausen T, Tschernig T, Rosenstiel P, van Griensven M, Vonberg R-P, Dorsch M, Mueller-Heine A, Chalaris A, Scheller J, Rose-John S (2011) Selective blockade of interleukin-6 trans-signaling improves survival in a murine polymicrobial sepsis model. Crit Care Med 39:1407\u20131413","journal-title":"Crit Care Med"},{"key":"1817_CR8","doi-asserted-by":"publisher","first-page":"5799","DOI":"10.3390\/jcm11195799","volume":"11","author":"C Baverez","year":"2022","unstructured":"Baverez C, Grall M, Gerfaud-Valentin M, de Gail S, Belot A, Perpoint T, Weber E, Reynaud Q, S\u00e8ve P, Jamilloux Y (2022) Anakinra for the treatment of hemophagocytic lymphohistiocytosis: 21 cases. J Clin Med 11:5799","journal-title":"J Clin Med"},{"key":"1817_CR9","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1136\/annrheumdis-2013-204816","volume":"74","author":"F Behrens","year":"2015","unstructured":"Behrens F, Tak PP, \u00d8stergaard M, Stoilov R, Wiland P, Huizinga TW, Berenfus VY, Vladeva S, Rech J, Rubbert-Roth A (2015) MOR103, a human monoclonal antibody to granulocyte\u2013macrophage colony-stimulating factor, in the treatment of patients with moderate rheumatoid arthritis: results of a phase Ib\/IIa randomised, double-blind, placebo-controlled, dose-escalation trial. Ann Rheum Dis 74:1058\u20131064","journal-title":"Ann Rheum Dis"},{"key":"1817_CR10","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1038\/nature04753","volume":"441","author":"E Bettelli","year":"2006","unstructured":"Bettelli E, Carrier Y, Gao W, Korn T, Strom TB, Oukka M, Weiner HL, Kuchroo VK (2006) Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 441:235\u2013238","journal-title":"Nature"},{"key":"1817_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1755-1536-6-13","volume":"6","author":"P Biancheri","year":"2013","unstructured":"Biancheri P, Pender SL, Ammoscato F, Giuffrida P, Sampietro G, Ardizzone S, Ghanbari A, Curciarello R, Pasini A, Monteleone G (2013) The role of interleukin 17 in Crohn\u2019s disease-associated intestinal fibrosis. Fibrogen Tissue Repair 6:1\u201312","journal-title":"Fibrogen Tissue Repair"},{"key":"1817_CR12","doi-asserted-by":"crossref","unstructured":"Boedigheimer MJ, Martin DA, Amoura Z, S\u00e1nchez-Guerrero J, Romero-Diaz J, Kivit A, Aranow C, Chan TM, Chong YB, Chiu K (2017) Safety, pharmacokinetics and pharmacodynamics of AMG 811, an anti-interferon-\u03b3 monoclonal antibody, in SLE subjects without or with lupus nephritis. Lupus Sci Med 4","DOI":"10.1136\/lupus-2017-000226"},{"key":"1817_CR13","doi-asserted-by":"publisher","first-page":"87","DOI":"10.2165\/00063030-200115020-00003","volume":"15","author":"B Bresnihan","year":"2001","unstructured":"Bresnihan B (2001) The prospect of treating rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. BioDrugs 15:87\u201397","journal-title":"BioDrugs"},{"key":"1817_CR14","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1111\/j.1600-065X.2012.01164.x","volume":"250","author":"SE Broughton","year":"2012","unstructured":"Broughton SE, Dhagat U, Hercus TR, Nero TL, Grimbaldeston MA, Bonder CS, Lopez AF, Parker MW (2012) The GM\u2013CSF\/IL-3\/IL-5 cytokine receptor family: from ligand recognition to initiation of signaling. Immunol Rev 250:277\u2013302","journal-title":"Immunol Rev"},{"key":"1817_CR15","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1136\/annrheumdis-2011-201244","volume":"72","author":"GR Burmester","year":"2013","unstructured":"Burmester GR, Panaccione R, Gordon KB, McIlraith MJ, Lacerda AP (2013) Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn\u2019s disease. Ann Rheum Dis 72:517\u2013524","journal-title":"Ann Rheum Dis"},{"key":"1817_CR16","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1136\/annrheumdis-2016-210624","volume":"76","author":"GR Burmester","year":"2017","unstructured":"Burmester GR, McInnes IB, Kremer J, Miranda P, Korkosz M, Vencovsky J, Rubbert-Roth A, Mysler E, Sleeman MA, Godwood A, Sinibaldi D, Guo X, White WI, Wang B, Wu CY, Ryan PC, Close D, Weinblatt ME (2017) A randomised phase IIb study of mavrilimumab, a novel GM-CSF receptor alpha monoclonal antibody, in the treatment of rheumatoid arthritis. Ann Rheum Dis 76:1020\u20131030","journal-title":"Ann Rheum Dis"},{"key":"1817_CR17","doi-asserted-by":"publisher","first-page":"273","DOI":"10.4049\/immunohorizons.2300003","volume":"7","author":"K Campbell","year":"2023","unstructured":"Campbell K, Li K, Yang F, Branigan P, Elloso MM, Benson J, Orlovsky Y, Chen Y, Garcet S, Krueger JG (2023) Guselkumab more effectively neutralizes psoriasis-associated histologic, transcriptomic, and clinical measures than ustekinumab. Immunohorizons 7:273\u2013285","journal-title":"Immunohorizons"},{"key":"1817_CR18","doi-asserted-by":"publisher","first-page":"S56","DOI":"10.1093\/ibd\/izae282.135","volume":"31","author":"S Cao","year":"2025","unstructured":"Cao S, Ma K, Deepak P (2025) IL-23-activated cells predict response to Risankizumab in Crohn\u2019s disease. Inflamm Bowel Dis 31:S56\u2013S57","journal-title":"Inflamm Bowel Dis"},{"key":"1817_CR19","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1038\/ncb0805-758","volume":"7","author":"ZJ Chen","year":"2005","unstructured":"Chen ZJ (2005) Ubiquitin signalling in the NF-\u03baB pathway. Nat Cell Biol 7:758\u2013765","journal-title":"Nat Cell Biol"},{"key":"1817_CR20","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1007\/s10753-021-01439-6","volume":"44","author":"M-Y Chen","year":"2021","unstructured":"Chen M-Y, Ye X-J, He X-H, Ouyang D-Y (2021) The signaling pathways regulating NLRP3 inflammasome activation. Inflammation 44:1229\u20131245","journal-title":"Inflammation"},{"key":"1817_CR21","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1136\/annrheumdis-2021-221865","volume":"81","author":"MC Cid","year":"2022","unstructured":"Cid MC, Unizony SH, Blockmans D, Brouwer E, Dagna L, Dasgupta B, Hellmich B, Molloy E, Salvarani C, Trapnell BC, Warrington KJ, Wicks I, Samant M, Zhou T, Pupim L, Paolini JF (2022) Efficacy and safety of mavrilimumab in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial. Ann Rheum Dis 81:653\u2013661","journal-title":"Ann Rheum Dis"},{"key":"1817_CR22","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1016\/S0140-6736(08)61620-7","volume":"372","author":"A Compston","year":"2008","unstructured":"Compston A, Coles A (2008) Multiple sclerosis. Lancet 372:1502\u20131517","journal-title":"Lancet"},{"key":"1817_CR23","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s12916-025-03870-0","volume":"23","author":"N Cox","year":"2025","unstructured":"Cox N, Mallen CD, Scott IC (2025) Pharmacological pain management in patients with rheumatoid arthritis: a narrative literature review. BMC Med 23:54","journal-title":"BMC Med"},{"key":"1817_CR24","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1038\/s41575-021-00543-0","volume":"19","author":"S D\u2019Alessio","year":"2022","unstructured":"D\u2019Alessio S, Ungaro F, Noviello D, Lovisa S, Peyrin-Biroulet L, Danese S (2022) Revisiting fibrosis in inflammatory bowel disease: the gut thickens. Nat Rev Gastroenterol Hepatol 19:169\u2013184","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"1817_CR25","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s40348-015-0024-4","volume":"2","author":"J D\u00e4britz","year":"2015","unstructured":"D\u00e4britz J (2015) GM-CSF and the role of myeloid regulatory cells in the pathogenesis and treatment of Crohn\u2019s disease. Mole Cell Pediat 2:12","journal-title":"Mole Cell Pediat"},{"key":"1817_CR26","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1093\/rheumatology\/kep329","volume":"49","author":"J-M Dayer","year":"2010","unstructured":"Dayer J-M, Choy E (2010) Therapeutic targets in rheumatoid arthritis: the interleukin-6 receptor. Rheumatology 49:15\u201324","journal-title":"Rheumatology"},{"key":"1817_CR27","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.berh.2017.08.003","volume":"31","author":"KD Deane","year":"2017","unstructured":"Deane KD, Demoruelle MK, Kelmenson LB, Kuhn KA, Norris JM, Holers VM (2017) Genetic and environmental risk factors for rheumatoid arthritis. Best Pract Res Clin Rheumatol 31:3\u201318","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"1817_CR28","doi-asserted-by":"publisher","first-page":"1124628","DOI":"10.3389\/fphar.2023.1124628","volume":"14","author":"Z Deng","year":"2023","unstructured":"Deng Z, Wang S, Wu C, Wang C (2023) IL-17 inhibitor-associated inflammatory bowel disease: a study based on literature and database analysis. Front Pharmacol 14:1124628","journal-title":"Front Pharmacol"},{"key":"1817_CR29","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.neuron.2009.09.002","volume":"64","author":"BE Deverman","year":"2009","unstructured":"Deverman BE, Patterson PH (2009) Cytokines and CNS development. Neuron 64:61\u201378","journal-title":"Neuron"},{"key":"1817_CR30","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1146\/annurev.immunol.021908.132612","volume":"27","author":"CA Dinarello","year":"2009","unstructured":"Dinarello CA (2009) Immunological and inflammatory functions of the interleukin-1 family. Annu Rev Immunol 27:519\u2013550","journal-title":"Annu Rev Immunol"},{"key":"1817_CR31","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1038\/ni1110-973","volume":"11","author":"C Dinarello","year":"2010","unstructured":"Dinarello C, Arend W, Sims J, Smith D, Blumberg H, O\u2019Neill L, Goldbach-Mansky R, Pizarro T, Hoffman H, Bufler P (2010) IL-1 family nomenclature. Nat Immunol 11:973\u2013973","journal-title":"Nat Immunol"},{"key":"1817_CR32","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/j.crohns.2012.04.008","volume":"7","author":"I Drygiannakis","year":"2013","unstructured":"Drygiannakis I, Valatas V, Sfakianaki O, Bourikas L, Manousou P, Kambas K, Ritis K, Kolios G, Kouroumalis E (2013) Proinflammatory cytokines induce crosstalk between colonic epithelial cells and subepithelial myofibroblasts: implication in intestinal fibrosis. J Crohns Colitis 7:286\u2013300","journal-title":"J Crohns Colitis"},{"key":"1817_CR33","doi-asserted-by":"crossref","unstructured":"Eugen Feist (2023) Interleukin 6 inhibition in rheumatoid arthritis: highlight on Olokizumab. Touch Immunol","DOI":"10.17925\/RMD.2023.2.1.17"},{"key":"1817_CR34","doi-asserted-by":"crossref","unstructured":"eun Lee Y, Lee S-H, Kim W-U (2024) Cytokines, vascular endothelial growth factors, and PlGF in autoimmunity: insights from rheumatoid arthritis to multiple sclerosis. Immune Netw 24","DOI":"10.4110\/in.2024.24.e10"},{"key":"1817_CR35","doi-asserted-by":"publisher","first-page":"17","DOI":"10.2217\/imt.15.95","volume":"8","author":"DC Fajgenbaum","year":"2016","unstructured":"Fajgenbaum DC, Kurzrock R (2016) Siltuximab: a targeted therapy for idiopathic multicentric Castleman disease. Immunotherapy 8:17\u201326","journal-title":"Immunotherapy"},{"key":"1817_CR36","doi-asserted-by":"publisher","first-page":"6181","DOI":"10.1007\/s00415-024-12590-z","volume":"271","author":"M Filippi","year":"2024","unstructured":"Filippi M, Pagani E, Turrini R, Bartezaghi M, Brescia Morra V, Borriello G, Torri Clerici V, Mirabella M (2024) Effects of fingolimod on focal and diffuse damage in patients with relapsing\u2013remitting multiple sclerosis\u2013The \u201cEVOLUTION\u201d study. J Neurol 271:6181\u20136196","journal-title":"J Neurol"},{"key":"1817_CR37","doi-asserted-by":"publisher","first-page":"1516","DOI":"10.1136\/ard-2023-224482","volume":"82","author":"RM Fleischmann","year":"2023","unstructured":"Fleischmann RM, van der Heijde D, Strand V, Atsumi T, McInnes IB, Takeuchi T, Taylor PC, Bracher M, Brooks D, Davies J (2023) Anti-GM-CSF otilimab versus tofacitinib or placebo in patients with active rheumatoid arthritis and an inadequate response to conventional or biologic DMARDs: two phase 3 randomised trials (contRAst 1 and contRAst 2). Ann Rheum Dis 82:1516\u20131526","journal-title":"Ann Rheum Dis"},{"key":"1817_CR38","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1001\/archinte.160.4.437","volume":"160","author":"DA Fox","year":"2000","unstructured":"Fox DA (2000) Cytokine blockade as a new strategy to treat rheumatoid arthritis: inhibition of tumor necrosis factor. Arch Intern Med 160:437\u2013444","journal-title":"Arch Intern Med"},{"key":"1817_CR39","first-page":"41","volume":"23","author":"T Fr\u00e9our","year":"2009","unstructured":"Fr\u00e9our T, Jarry A, Bach-Ngohou K, Dejoie T, Bou-Hanna C, Denis MG, Mosnier J-F, Laboisse CL, Masson D (2009) TACE inhibition amplifies TNF-\u03b1-mediated colonic epithelial barrier disruption. Int J Mol Med 23:41\u201348","journal-title":"Int J Mol Med"},{"key":"1817_CR40","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1177\/2040622317738910","volume":"9","author":"J Frieder","year":"2018","unstructured":"Frieder J, Kivelevitch D, Menter A (2018) Secukinumab: a review of the anti-IL-17A biologic for the treatment of psoriasis. Ther Adv Chronic Dis 9:5\u201321","journal-title":"Ther Adv Chronic Dis"},{"key":"1817_CR41","doi-asserted-by":"publisher","first-page":"784","DOI":"10.3390\/cells8080784","volume":"8","author":"X Fu","year":"2019","unstructured":"Fu X, Liu G, Halim A, Ju Y, Luo Q, Song G (2019) Mesenchymal stem cell migration and tissue repair. Cells 8:784","journal-title":"Cells"},{"key":"1817_CR42","doi-asserted-by":"publisher","first-page":"1218082","DOI":"10.3389\/fimmu.2023.1218082","volume":"14","author":"Y Fu","year":"2023","unstructured":"Fu Y, Tang R, Zhao X (2023) Engineering cytokines for cancer immunotherapy: a systematic review. Front Immunol 14:1218082","journal-title":"Front Immunol"},{"key":"1817_CR43","doi-asserted-by":"publisher","first-page":"347","DOI":"10.3390\/biology14040347","volume":"14","author":"M Garc\u00eda-dom\u00ednguez","year":"2025","unstructured":"Garc\u00eda-dom\u00ednguez M (2025) The role of IL-23 in the development of inflammatory diseases. Biology 14:347","journal-title":"Biology"},{"key":"1817_CR44","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1182\/blood-2022-167703","volume":"140","author":"G Garcia-Manero","year":"2022","unstructured":"Garcia-Manero G, Adema V, Urrutia S, Ma F, Yang H, Ganan-Gomez I, Borthakur G, Takahashi K, Short N, Issa GC, Chien KS, Montalban-Bravo G, Joseph J, Colla S (2022) Clinical and biological effects of canakinumab in lower-risk myelodysplastic syndromes (MDS): results from a phase 2 clinical trial. Blood 140:2078\u20132080","journal-title":"Blood"},{"key":"1817_CR45","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1053\/gast.1996.v110.pm8566579","volume":"110","author":"MF Graham","year":"1996","unstructured":"Graham MF, Willey A, Adams J, Yager D, Diegelmann RF (1996) Interleukin 1 beta down-regulates collagen and augments collagenase expression in human intestinal smooth muscle cells. Gastroenterology 110:344\u2013350","journal-title":"Gastroenterology"},{"key":"1817_CR46","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.ccr.2009.01.001","volume":"15","author":"S Grivennikov","year":"2009","unstructured":"Grivennikov S, Karin E, Terzic J, Mucida D, Yu G-Y, Vallabhapurapu S, Scheller J, Rose-John S, Cheroutre H, Eckmann L (2009) IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell 15:103\u2013113","journal-title":"Cancer Cell"},{"key":"1817_CR47","doi-asserted-by":"publisher","first-page":"1190333","DOI":"10.3389\/fimmu.2023.1190333","volume":"14","author":"J Han","year":"2023","unstructured":"Han J, Wu M, Liu Z (2023) Dysregulation in IFN-\u03b3 signaling and response: the barricade to tumor immunotherapy. Front Immunol 14:1190333","journal-title":"Front Immunol"},{"key":"1817_CR48","doi-asserted-by":"publisher","first-page":"5","DOI":"10.2174\/1389557013407214","volume":"1","author":"A Hasegawa","year":"2001","unstructured":"Hasegawa A, Takasaki W, Greene MI, Murali R (2001) Modifying TNF alpha for therapeutic use a perspective on the tnf receptor system. Mini Rev Med Chem 1:5\u201316","journal-title":"Mini Rev Med Chem"},{"key":"1817_CR49","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.cytogfr.2013.03.002","volume":"24","author":"TR Hercus","year":"2013","unstructured":"Hercus TR, Dhagat U, Kan WL, Broughton SE, Nero TL, Perugini M, Sandow JJ, D\u2019Andrea RJ, Ekert PG, Hughes T (2013) Signalling by the \u03b2c family of cytokines. Cytokine Growth Factor Rev 24:189\u2013201","journal-title":"Cytokine Growth Factor Rev"},{"key":"1817_CR50","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1007\/s11011-012-9323-9","volume":"27","author":"C Hocaoglu","year":"2012","unstructured":"Hocaoglu C, Kural B, Aliyaz\u0131c\u0131oglu R, Deger O, Cengiz S (2012) IL-1\u03b2, IL-6, IL-8, IL-10, IFN-\u03b3, TNF-\u03b1 and its relationship with lipid parameters in patients with major depression. Metab Brain Dis 27:425\u2013430","journal-title":"Metab Brain Dis"},{"key":"1817_CR51","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1055\/s-2002-33418","volume":"40","author":"M Holtmann","year":"2002","unstructured":"Holtmann M, Sch\u00fctz M, Galle P, Neurath M (2002) Functional relevance of soluble TNF-\u03b1, transmembrane TNF-\u03b1 and TNF-signal transduction in gastrointestinal diseases with special reference to inflammatory bowel diseases. Z Gastroenterol 40:587\u2013600","journal-title":"Z Gastroenterol"},{"key":"1817_CR52","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1136\/gut.2005.079392","volume":"55","author":"DW Hommes","year":"2006","unstructured":"Hommes DW, Mikhajlova TL, Stoinov S, \u0160timac D, Vucelic B, Lonovics J, Z\u00e1kuciov\u00e1 M, D\u2019Haens G, van Assche G, Ba S (2006) Fontolizumab, a humanised anti-interferon \u03b3 antibody, demonstrates safety and clinical activity in patients with moderate to severe Crohn\u2019s disease. Gut 55:1131\u20131137","journal-title":"Gut"},{"key":"1817_CR53","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1093\/rheumatology\/keq031","volume":"49","author":"T Horiuchi","year":"2010","unstructured":"Horiuchi T, Mitoma H, Harashima S-I, Tsukamoto H, Shimoda T (2010) Transmembrane TNF-\u03b1: structure, function and interaction with anti-TNF agents. Rheumatology 49:1215\u20131228","journal-title":"Rheumatology"},{"key":"1817_CR54","doi-asserted-by":"publisher","first-page":"3913","DOI":"10.1073\/pnas.1217996110","volume":"110","author":"J Hou","year":"2013","unstructured":"Hou J, Townson SA, Kovalchin JT, Masci A, Kiner O, Shu Y, King BM, Schirmer E, Golden K, Thomas C (2013) Design of a superior cytokine antagonist for topical ophthalmic use. Proc Natl Acad Sci 110:3913\u20133918","journal-title":"Proc Natl Acad Sci"},{"key":"1817_CR55","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/s41551-020-00627-3","volume":"5","author":"A Ishihara","year":"2021","unstructured":"Ishihara A, Ishihara J, Watkins EA, Tremain AC, Nguyen M, Solanki A, Katsumata K, Mansurov A, Budina E, Alpar AT, Hosseinchi P, Maillat L, Reda JW, Kageyama T, Swartz MA, Yuba E, Hubbell JA (2021) Prolonged residence of an albumin\u2013IL-4 fusion protein in secondary lymphoid organs ameliorates experimental autoimmune encephalomyelitis. Nat Biomed Eng 5:387\u2013398","journal-title":"Nat Biomed Eng"},{"key":"1817_CR56","doi-asserted-by":"crossref","unstructured":"Kang Y-J, Cho HJ, Lee Y, Park A, Kim MJ, Jeung IC, Jung Y-W, Jung H, Choi I, Lee HG (2023) IL-17A and Th17 cells contribute to endometrial cell survival by inhibiting apoptosis and NK cell mediated cytotoxicity of endometrial cells via ERK1\/2 pathway. Immune Netw 23","DOI":"10.4110\/in.2023.23.e14"},{"key":"1817_CR57","doi-asserted-by":"publisher","first-page":"S2","DOI":"10.1212\/WNL.0b013e3181c97c8f","volume":"74","author":"LH Kasper","year":"2010","unstructured":"Kasper LH, Shoemaker J (2010) Multiple sclerosis immunology: the healthy immune system vs the MS immune system. Neurology 74:S2\u2013S8","journal-title":"Neurology"},{"key":"1817_CR58","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1080\/25785826.2020.1751908","volume":"43","author":"M Kato","year":"2020","unstructured":"Kato M (2020) New insights into IFN-\u03b3 in rheumatoid arthritis: role in the era of JAK inhibitors. Immunol Med 43:72\u201378","journal-title":"Immunol Med"},{"key":"1817_CR59","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s41232-024-00355-0","volume":"44","author":"H Kayama","year":"2024","unstructured":"Kayama H, Takeda K (2024) Regulation of intestinal epithelial homeostasis by mesenchymal cells. Inflamm Regen 44:42","journal-title":"Inflamm Regen"},{"key":"1817_CR60","first-page":"390","volume":"66","author":"H Kebir","year":"2009","unstructured":"Kebir H, Ifergan I, Alvarez JI, Bernard M, Poirier J, Arbour N, Duquette P, Prat A (2009) Preferential recruitment of interferon-\u03b3\u2013expressing TH17 cells in multiple sclerosis. Ann Neurol Offic J Am Neurol Assoc Child Neurol Soc 66:390\u2013402","journal-title":"Ann Neurol Offic J Am Neurol Assoc Child Neurol Soc"},{"key":"1817_CR61","doi-asserted-by":"publisher","first-page":"1830","DOI":"10.1002\/eji.201040391","volume":"40","author":"A Kimura","year":"2010","unstructured":"Kimura A, Kishimoto T (2010) IL-6: regulator of Treg\/Th17 balance. Eur J Immunol 40:1830\u20131835","journal-title":"Eur J Immunol"},{"key":"1817_CR62","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1146\/annurev.immunol.021908.132710","volume":"27","author":"T Korn","year":"2009","unstructured":"Korn T, Bettelli E, Oukka M, Kuchroo VK (2009) IL-17 and Th17 Cells. Annu Rev Immunol 27:485\u2013517","journal-title":"Annu Rev Immunol"},{"key":"1817_CR63","doi-asserted-by":"publisher","first-page":"1331217","DOI":"10.3389\/fimmu.2024.1331217","volume":"15","author":"JG Krueger","year":"2024","unstructured":"Krueger JG, Eyerich K, Kuchroo VK, Ritchlin CT, Abreu MT, Elloso MM, Fourie A, Fakharzadeh S, Sherlock JP, Yang Y-W (2024) IL-23 past, present, and future: a roadmap to advancing IL-23 science and therapy. Front Immunol 15:1331217","journal-title":"Front Immunol"},{"key":"1817_CR64","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1186\/s12967-024-05058-1","volume":"22","author":"M Kumar","year":"2024","unstructured":"Kumar M, Murugesan S, Ibrahim N, Elawad M, AL Khodor S (2024) Predictive biomarkers for anti-TNF alpha therapy in IBD patients. J Transl Med 22:284","journal-title":"J Transl Med"},{"key":"1817_CR65","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1007\/s00296-016-3480-9","volume":"36","author":"S Kunwar","year":"2016","unstructured":"Kunwar S, Dahal K, Sharma S (2016) Anti-IL-17 therapy in treatment of rheumatoid arthritis: a systematic literature review and meta-analysis of randomized controlled trials. Rheumatol Int 36:1065\u20131075","journal-title":"Rheumatol Int"},{"key":"1817_CR66","first-page":"9","volume":"118","author":"P Lacy","year":"2011","unstructured":"Lacy P, Stow JL (2011) Cytokine release from innate immune cells: association with diverse membrane trafficking pathways. Blood J Am Soc Hematol 118:9\u201318","journal-title":"Blood J Am Soc Hematol"},{"key":"1817_CR67","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1146\/annurev-cellbio-101011-155745","volume":"28","author":"M Lamkanfi","year":"2012","unstructured":"Lamkanfi M, Dixit VM (2012) Inflammasomes and their roles in health and disease. Annu Rev Cell Dev Biol 28:137\u2013161","journal-title":"Annu Rev Cell Dev Biol"},{"key":"1817_CR68","doi-asserted-by":"publisher","first-page":"4691","DOI":"10.1172\/JCI124884","volume":"129","author":"V Langer","year":"2019","unstructured":"Langer V, Vivi E, Regensburger D, Winkler TH, Waldner MJ, Rath T, Schmid B, Skottke L, Lee S, Jeon NL (2019) IFN-\u03b3 drives inflammatory bowel disease pathogenesis through VE-cadherin\u2013directed vascular barrier disruption. J Clin Investig 129:4691\u20134707","journal-title":"J Clin Investig"},{"key":"1817_CR69","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1186\/s13075-024-03380-z","volume":"26","author":"KM-C Lee","year":"2024","unstructured":"Lee KM-C, Lupancu T, Chang L, Manthey CL, Zeeman M, Fourie AM, Hamilton JA (2024) The mode of action of IL-23 in experimental inflammatory arthritic pain and disease. Arthritis Res Ther 26:148","journal-title":"Arthritis Res Ther"},{"key":"1817_CR70","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1016\/j.gastro.2003.07.004","volume":"125","author":"SN Leeb","year":"2003","unstructured":"Leeb SN, Vogl D, Gunckel M, Kiessling S, Falk W, G\u00f6ke M, Sch\u00f6lmerich J, Gelbmann CM, Rogler G (2003) Reduced migration of fibroblasts in inflammatory bowel disease: role of inflammatory mediators and focal adhesion kinase. Gastroenterology 125:1341\u20131354","journal-title":"Gastroenterology"},{"key":"1817_CR71","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1038\/nri2156","volume":"7","author":"K Ley","year":"2007","unstructured":"Ley K, Laudanna C, Cybulsky MI, Nourshargh S (2007) Getting to the site of inflammation: the leukocyte adhesion cascade updated. Nat Rev Immunol 7:678\u2013689","journal-title":"Nat Rev Immunol"},{"key":"1817_CR72","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1097\/MIB.0000000000000043","volume":"20","author":"C Li","year":"2014","unstructured":"Li C, Kuemmerle JF (2014) Mechanisms that mediate the development of fibrosis in patients with Crohn\u2019s disease. Inflamm Bowel Dis 20:1250\u20131258","journal-title":"Inflamm Bowel Dis"},{"key":"1817_CR73","doi-asserted-by":"publisher","first-page":"3422","DOI":"10.4049\/jimmunol.1401779","volume":"194","author":"C Li","year":"2015","unstructured":"Li C, Iness A, Yoon J, Grider JR, Murthy KS, Kellum JM, Kuemmerle JF (2015) Noncanonical STAT3 activation regulates excess TGF-\u03b21 and collagen I expression in muscle of stricturing Crohn\u2019s disease. J Immunol 194:3422\u20133431","journal-title":"J Immunol"},{"key":"1817_CR74","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.mrgentox.2011.10.012","volume":"741","author":"J Liu","year":"2012","unstructured":"Liu J, Ouyang M, Jiang J, Mu P, Wu J, Yang Q, Zhang C, Xu W, Wang L, Huen MS, Deng Y (2012) Mequindox induced cellular DNA damage via generation of reactive oxygen species. Mutat Res 741:70\u201375","journal-title":"Mutat Res"},{"key":"1817_CR75","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.594735","volume":"11","author":"T Liu","year":"2020","unstructured":"Liu T, Li S, Ying S, Tang S, Ding Y, Li Y, Qiao J, Fang H (2020) The IL-23\/IL-17 pathway in inflammatory skin diseases: from bench to bedside. Front Immunol 11:594735","journal-title":"Front Immunol"},{"key":"1817_CR76","doi-asserted-by":"publisher","first-page":"409","DOI":"10.2174\/157015911796557911","volume":"9","author":"I Loma","year":"2011","unstructured":"Loma I, Heyman R (2011) Multiple sclerosis: pathogenesis and treatment. Curr Neuropharmacol 9:409\u2013416","journal-title":"Curr Neuropharmacol"},{"key":"1817_CR77","doi-asserted-by":"crossref","unstructured":"Lovett-racke AE, Racke MK (2018) Role of IL-12\/Il-23 in the pathogenesis of multiple sclerosis. Neuroinflammation pp 115\u2013139","DOI":"10.1016\/B978-0-12-811709-5.00005-3"},{"key":"1817_CR78","doi-asserted-by":"publisher","first-page":"1284304","DOI":"10.3389\/fneur.2023.1284304","volume":"14","author":"Y Lu","year":"2023","unstructured":"Lu Y, Zhang P, Xu F, Zheng Y, Zhao H (2023) Advances in the study of IL-17 in neurological diseases and mental disorders. Front Neurol 14:1284304","journal-title":"Front Neurol"},{"key":"1817_CR79","doi-asserted-by":"publisher","first-page":"2687","DOI":"10.1242\/jcs.00471","volume":"116","author":"A Mandinova","year":"2003","unstructured":"Mandinova A, Soldi R, Graziani I, Bagal\u00e1 C, Bellum S, Landriscina M, Tarantini F, Prudovsky I, Maciag T (2003) S100A13 mediates the copper-dependent stress-induced release of IL-1\u03b1 from both human U937 and murine NIH 3T3 cells. J Cell Sci 116:2687\u20132696","journal-title":"J Cell Sci"},{"key":"1817_CR80","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1177\/0976500X221105921","volume":"13","author":"D Manoharan","year":"2022","unstructured":"Manoharan D, Ravi Vignesh N, Shreya S, Suzsmi LS (2022) Secukinumab: a silver lining in dermatology. J Pharmacol Pharmacotherapeutics 13:119\u2013124","journal-title":"J Pharmacol Pharmacotherapeutics"},{"key":"1817_CR81","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.652846","volume":"12","author":"P Martin","year":"2021","unstructured":"Martin P, Goldstein JD, Mermoud L, Diaz-Barreiro A, Palmer G (2021) IL-1 family antagonists in mouse and human skin inflammation. Front Immunol 12:652846","journal-title":"Front Immunol"},{"key":"1817_CR82","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.cca.2016.02.010","volume":"455","author":"S Mateen","year":"2016","unstructured":"Mateen S, Zafar A, Moin S, Khan AQ, Zubair S (2016) Understanding the role of cytokines in the pathogenesis of rheumatoid arthritis. Clin Chim Acta 455:161\u2013171","journal-title":"Clin Chim Acta"},{"key":"1817_CR83","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1186\/s12974-024-03193-6","volume":"21","author":"V Mazziotti","year":"2024","unstructured":"Mazziotti V, Crescenzo F, Turano E, Guandalini M, Bertolazzo M, Ziccardi S, Virla F, Camera V, Marastoni D, Tamanti A, Calabrese M (2024) The contribution of tumor necrosis factor to multiple sclerosis: a possible role in progression independent of relapse? J Neuroinflammation 21:209","journal-title":"J Neuroinflammation"},{"key":"1817_CR84","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1038\/nri2094","volume":"7","author":"IB McInnes","year":"2007","unstructured":"McInnes IB, Schett G (2007) Cytokines in the pathogenesis of rheumatoid arthritis. Nat Rev Immunol 7:429\u2013442","journal-title":"Nat Rev Immunol"},{"key":"1817_CR85","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1186\/s12876-024-03218-7","volume":"24","author":"A Menesy","year":"2024","unstructured":"Menesy A, Hammad M, Aref S, Abozeid FAM (2024) Level of interleukin 17 in inflammatory bowel disease and its relation with disease activity. BMC Gastroenterol 24:135","journal-title":"BMC Gastroenterol"},{"key":"1817_CR86","doi-asserted-by":"publisher","first-page":"947","DOI":"10.3389\/fimmu.2020.00947","volume":"11","author":"J Milovanovic","year":"2020","unstructured":"Milovanovic J, Arsenijevic A, Stojanovic B, Kanjevac T, Arsenijevic D, Radosavljevic G, Milovanovic M, Arsenijevic N (2020) Interleukin-17 in chronic inflammatory neurological diseases. Front Immunol 11:947","journal-title":"Front Immunol"},{"key":"1817_CR87","doi-asserted-by":"publisher","first-page":"12","DOI":"10.33545\/comed.2023.v6.i3a.269","volume":"6","author":"S Mohammed","year":"2023","unstructured":"Mohammed S (2023) IL-12, IL-23 and IL-17 in IBD: Therapeutic and immunobiology targeting. Int J Adv Commun Med 6:12\u201316","journal-title":"Int J Adv Commun Med"},{"key":"1817_CR88","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1186\/s12964-024-01668-w","volume":"22","author":"X Mu","year":"2024","unstructured":"Mu X, Gu R, Tang M, Wu X, He W, Nie X (2024) IL-17 in wound repair: bridging acute and chronic responses. Cell Commun Signal 22:288","journal-title":"Cell Commun Signal"},{"key":"1817_CR89","unstructured":"Multum (2024) Tocilizumab. drugs.com."},{"key":"1817_CR90","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1517\/14712598.2012.732062","volume":"12","author":"JR Nair","year":"2012","unstructured":"Nair JR, Edwards SW, Moots RJ (2012) Mavrilimumab, a human monoclonal GM-CSF receptor-\u03b1 antibody for the management of rheumatoid arthritis: a novel approach to therapy. Expert Opin Biol Ther 12:1661\u20131668","journal-title":"Expert Opin Biol Ther"},{"key":"1817_CR91","doi-asserted-by":"publisher","first-page":"3449","DOI":"10.1182\/blood-2024-205205","volume":"144","author":"MS Narkhede","year":"2024","unstructured":"Narkhede MS, di Stasi A, Shea LK, Bal S, Ravi G, Goyal G, Hardwick P, Giri S, Salzman D, Bhatia R (2024) Phase 2 trial of siltuximab for the treatment of cytokine release syndrome and immune effector cell associated neurotoxicity related to CAR-T cell therapy. Blood 144:3449","journal-title":"Blood"},{"key":"1817_CR92","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1158\/2326-6066.CIR-18-0622","volume":"7","author":"D Neri","year":"2019","unstructured":"Neri D (2019) Antibody\u2013cytokine fusions: versatile products for the modulation of anticancer immunity. Cancer Immunol Res 7:348\u2013354","journal-title":"Cancer Immunol Res"},{"key":"1817_CR93","doi-asserted-by":"crossref","unstructured":"Neurath MF (2024) Strategies for targeting cytokines in inflammatory bowel disease. Nat Rev Immunol pp 1\u201318","DOI":"10.1038\/s41577-024-01008-6"},{"key":"1817_CR94","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s12974-021-02140-z","volume":"18","author":"L Nitsch","year":"2021","unstructured":"Nitsch L, Petzinna S, Zimmermann J, Schneider L, Krauthausen M, Heneka MT, Getts DR, Becker A, M\u00fcller M (2021) Astrocyte-specific expression of interleukin 23 leads to an aggravated phenotype and enhanced inflammatory response with B cell accumulation in the EAE model. J Neuroinflammation 18:101","journal-title":"J Neuroinflammation"},{"key":"1817_CR95","doi-asserted-by":"publisher","first-page":"3357","DOI":"10.1182\/blood.V95.11.3357","volume":"95","author":"L Niu","year":"2000","unstructured":"Niu L, Heaney ML, Vera JC, Golde DW (2000) High-affinity binding to the GM-CSF receptor requires intact N-glycosylation sites in the extracellular domain of the \u03b2 subunit. Blood 95:3357\u20133362","journal-title":"Blood"},{"key":"1817_CR96","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1111\/j.1600-065X.2008.00701.x","volume":"226","author":"LA O\u2019neill","year":"2008","unstructured":"O\u2019neill LA (2008) The interleukin-1 receptor\/Toll-like receptor superfamily: 10 years of progress. Immunol Rev 226:10\u201318","journal-title":"Immunol Rev"},{"key":"1817_CR97","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1080\/003655202317284228","volume":"37","author":"T Okuno","year":"2002","unstructured":"Okuno T, Andoh A, Bamba S, Araki Y, Fujiyama Y, Fujimiya M, Bamba T (2002) Interleukin-1\u03b2 and tumor necrosis factor-\u03b1 induce chemokine and matrix metalloproteinase gene expression in human colonic subepithelial myofibroblasts. Scand J Gastroenterol 37:317\u2013324","journal-title":"Scand J Gastroenterol"},{"key":"1817_CR98","doi-asserted-by":"publisher","first-page":"2242","DOI":"10.3390\/cells10092242","volume":"10","author":"M Olbei","year":"2021","unstructured":"Olbei M, Thomas JP, Hautefort I, Treveil A, Bohar B, Madgwick M, Gul L, Csabai L, Modos D, Korcsmaros T (2021) CytokineLink: a cytokine communication map to analyse immune responses\u2014case studies in inflammatory bowel disease and COVID-19. Cells 10:2242","journal-title":"Cells"},{"key":"1817_CR99","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1007\/s13238-010-0017-y","volume":"1","author":"K Ono","year":"2010","unstructured":"Ono K, Wang X, Kim SO, Armstrong LC, Bornstein P, Han J (2010) Metaxin deficiency alters mitochondrialmembrane permeability and leads to resistance to TNF-induced cell killing. Protein Cell 1:161\u2013173","journal-title":"Protein Cell"},{"key":"1817_CR100","first-page":"23","volume":"5","author":"P Palle","year":"2017","unstructured":"Palle P, Monaghan KL, Milne SM, Wan EC (2017) Cytokine signaling in multiple sclerosis and its therapeutic applications. Med Sci 5:23","journal-title":"Med Sci"},{"key":"1817_CR101","doi-asserted-by":"publisher","first-page":"5238","DOI":"10.3390\/ijms21155238","volume":"21","author":"F Pandolfi","year":"2020","unstructured":"Pandolfi F, Franza L, Carusi V, Altamura S, Andriollo G, Nucera E (2020) Interleukin-6 in rheumatoid arthritis. Int J Mol Sci 21:5238","journal-title":"Int J Mol Sci"},{"key":"1817_CR102","doi-asserted-by":"crossref","unstructured":"Patel J, Beishuizen A, Ruiz XB, Boughanmi H, Cahn A, Criner GJ, Davy K, De-Miguel-D\u00edez J, Fernandes S, Fran\u00e7ois B (2021) A randomized trial of otilimab in severe COVID-19 pneumonia (OSCAR). medRxiv","DOI":"10.1101\/2021.04.14.21255475"},{"key":"1817_CR103","doi-asserted-by":"publisher","first-page":"3233","DOI":"10.4049\/jimmunol.0903271","volume":"184","author":"SR Pickens","year":"2010","unstructured":"Pickens SR, Volin MV, Mandelin AM, Kolls JK, Pope RM, Shahrara S (2010) IL-17 contributes to angiogenesis in rheumatoid arthritis. J Immunol 184:3233\u20133241","journal-title":"J Immunol"},{"key":"1817_CR104","doi-asserted-by":"crossref","unstructured":"Pierson ER, Goverman JM (2017) GM-CSF is not essential for experimental autoimmune encephalomyelitis but promotes brain-targeted disease. JCI Insight","DOI":"10.1172\/jci.insight.92362"},{"key":"1817_CR105","doi-asserted-by":"publisher","first-page":"4871","DOI":"10.1242\/jcs.00872","volume":"116","author":"I Prudovsky","year":"2003","unstructured":"Prudovsky I, Mandinova A, Soldi R, Bagala C, Graziani I, Landriscina M, Tarantini F, Duarte M, Bellum S, Doherty H (2003) The non-classical export routes: FGF1 and IL-1\u03b1 point the way. J Cell Sci 116:4871\u20134881","journal-title":"J Cell Sci"},{"key":"1817_CR106","unstructured":"Puckey M (2024) Adalimumab. drugs.com"},{"key":"1817_CR107","doi-asserted-by":"publisher","first-page":"7100","DOI":"10.3390\/ijms21197100","volume":"21","author":"C Rafael-Vidal","year":"2020","unstructured":"Rafael-Vidal C, P\u00e9rez N, Altab\u00e1s I, Garcia S, Pego-Reigosa JM (2020) Blocking IL-17: a promising strategy in the treatment of systemic rheumatic diseases. Int J Mol Sci 21:7100","journal-title":"Int J Mol Sci"},{"key":"1817_CR108","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1136\/annrheumdis-2014-206578","volume":"75","author":"G Reynolds","year":"2016","unstructured":"Reynolds G, Gibbon J, Pratt A, Wood M, Coady D, Raftery G, Lorenzi A, Gray A, Filer A, Buckley C (2016) Synovial CD4+ T-cell-derived GM-CSF supports the differentiation of an inflammatory dendritic cell population in rheumatoid arthritis. Ann Rheum Dis 75:899\u2013907","journal-title":"Ann Rheum Dis"},{"key":"1817_CR109","doi-asserted-by":"publisher","first-page":"886","DOI":"10.4049\/jimmunol.162.2.886","volume":"162","author":"W Rohn","year":"1999","unstructured":"Rohn W, Tang LP, Dong Y, Benveniste EN (1999) IL-1\u03b2 inhibits IFN-\u03b3-induced class II MHC expression by suppressing transcription of the class II transactivator gene. J Immunol 162:886\u2013896","journal-title":"J Immunol"},{"key":"1817_CR110","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1186\/s12967-019-1965-5","volume":"17","author":"MS Saddala","year":"2019","unstructured":"Saddala MS, Huang H (2019) Identification of novel inhibitors for TNF\u03b1, TNFR1 and TNF\u03b1-TNFR1 complex using pharmacophore-based approaches. J Transl Med 17:215","journal-title":"J Transl Med"},{"key":"1817_CR111","doi-asserted-by":"publisher","first-page":"29","DOI":"10.5152\/eurjrheum.2018.18099","volume":"6","author":"G Sarg\u0131n","year":"2018","unstructured":"Sarg\u0131n G, K\u00f6se R, \u015eent\u00fcrk T (2018) Relationship between bone mineral density and anti-citrullinated protein antibody and rheumatoid factor in patients with rheumatoid arthritis. Eur J Rheumatol 6:29","journal-title":"Eur J Rheumatol"},{"key":"1817_CR112","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1177\/2040620716653745","volume":"7","author":"S Sarosiek","year":"2016","unstructured":"Sarosiek S, Shah R, Munshi NC (2016) Review of siltuximab in the treatment of multicentric Castleman\u2019s disease. Therapeut Adv Hematol 7:360\u2013366","journal-title":"Therapeut Adv Hematol"},{"key":"1817_CR113","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0112408","volume":"9","author":"K Sato","year":"2014","unstructured":"Sato K, Takaishi M, Tokuoka S, Sano S (2014) Involvement of TNF-\u03b1 converting enzyme in the development of psoriasis-like lesions in a mouse model. PLoS ONE 9:e112408","journal-title":"PLoS ONE"},{"key":"1817_CR114","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/j.it.2011.05.005","volume":"32","author":"J Scheller","year":"2011","unstructured":"Scheller J, Chalaris A, Garbers C, Rose-John S (2011) ADAM17: a molecular switch to control inflammation and tissue regeneration. Trends Immunol 32:380\u2013387","journal-title":"Trends Immunol"},{"key":"1817_CR115","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1186\/s13075-023-03098-4","volume":"25","author":"N Schlesinger","year":"2023","unstructured":"Schlesinger N, Pillinger MH, Simon LS, Lipsky PE (2023) Interleukin-1\u03b2 inhibitors for the management of acute gout flares: a systematic literature review. Arthritis Res Ther 25:128","journal-title":"Arthritis Res Ther"},{"key":"1817_CR116","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/s12079-022-00695-x","volume":"17","author":"A Shahini","year":"2023","unstructured":"Shahini A, Shahini A (2023) Role of interleukin-6-mediated inflammation in the pathogenesis of inflammatory bowel disease: focus on the available therapeutic approaches and gut microbiome. J Cell Commun Signal 17:55\u201374","journal-title":"J Cell Commun Signal"},{"key":"1817_CR117","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s41232-016-0014-5","volume":"36","author":"A Shiomi","year":"2016","unstructured":"Shiomi A, Usui T, Mimori T (2016) GM-CSF as a therapeutic target in autoimmune diseases. Inflamm Regen 36:8","journal-title":"Inflamm Regen"},{"key":"1817_CR118","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1016\/S0140-6736(16)30173-8","volume":"388","author":"J Smolen","year":"2016","unstructured":"Smolen J (2016) Aletaha d, McInnes IB rheumatoid arthritis. Lancet 388:2023\u20132038","journal-title":"Lancet"},{"key":"1817_CR119","doi-asserted-by":"publisher","first-page":"S2","DOI":"10.1186\/1478-6354-13-S1-S2","volume":"13","author":"JS Smolen","year":"2011","unstructured":"Smolen JS, Emery P (2011) Infliximab: 12 years of experience. Arthritis Res Ther 13:S2","journal-title":"Arthritis Res Ther"},{"key":"1817_CR120","doi-asserted-by":"crossref","unstructured":"Song MS (2024) The usefulness of infliximab treatment in the acute phase of Kawasaki disease. Kawasaki Disease 2","DOI":"10.59492\/kd.2024.2.1.e1"},{"key":"1817_CR121","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1177\/1759720X10378372","volume":"2","author":"S Srirangan","year":"2010","unstructured":"Srirangan S, Choy EH (2010) The role of interleukin 6 in the pathophysiology of rheumatoid arthritis. Ther Adv Musculoskeletal Disease 2:247\u2013256","journal-title":"Ther Adv Musculoskeletal Disease"},{"key":"1817_CR122","doi-asserted-by":"publisher","first-page":"120","DOI":"10.3389\/fncel.2020.00120","volume":"14","author":"M Stampanoni Bassi","year":"2020","unstructured":"Stampanoni Bassi M, Iezzi E, Drulovic J, Pekmezovic T, Gilio L, Furlan R, Finardi A, Marfia GA, Sica F, Centonze D (2020) IL-6 in the cerebrospinal fluid signals disease activity in multiple sclerosis. Front Cell Neurosci 14:120","journal-title":"Front Cell Neurosci"},{"key":"1817_CR123","doi-asserted-by":"crossref","unstructured":"Stampanoni-Bassi M, Iezzi E, Drulovic J, Pekmezovic T, Gilio L, Furlan R, Finardi A, Marfia GA, Sica F, Centonze D, Buttari F (2020b) IL-6 in the cerebrospinal fluid signals disease activity in multiple sclerosis. Front Cell Neurosci 14","DOI":"10.3389\/fncel.2020.00120"},{"key":"1817_CR124","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.3390\/ijms25021009","volume":"25","author":"N Stanilov","year":"2024","unstructured":"Stanilov N, Velikova T, Stanilova S (2024) Navigating the cytokine seas: targeting cytokine signaling pathways in cancer therapy. Int J Mol Sci 25:1009","journal-title":"Int J Mol Sci"},{"key":"1817_CR125","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.molimm.2008.07.013","volume":"46","author":"S Steidl","year":"2008","unstructured":"Steidl S, Ratsch O, Brocks B, D\u00fcrr M, Thomassen-Wolf E (2008) In vitro affinity maturation of human GM-CSF antibodies by targeted CDR-diversification. Mol Immunol 46:135\u2013144","journal-title":"Mol Immunol"},{"key":"1817_CR126","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1186\/s13075-020-02344-3","volume":"22","author":"V Strand","year":"2020","unstructured":"Strand V, Boklage SH, Kimura T, Joly F, Boyapati A, Msihid J (2020) High levels of interleukin-6 in patients with rheumatoid arthritis are associated with greater improvements in health-related quality of life for sarilumab compared with adalimumab. Arthritis Res Ther 22:250","journal-title":"Arthritis Res Ther"},{"key":"1817_CR127","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1186\/ar1136","volume":"6","author":"J Strunk","year":"2004","unstructured":"Strunk J, Heinemann E, Lange U (2004) Anti-TNF-\u03b1 antibody Infliximab and glucocorticoids reduce serum vascular endothelial growth factor (VEGF) levels in patients with rheumatoid arthritis: a pilot study. Arthritis Res Ther 6:94","journal-title":"Arthritis Res Ther"},{"key":"1817_CR128","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.3389\/fimmu.2019.01293","volume":"10","author":"S Swaidani","year":"2019","unstructured":"Swaidani S, Liu C, Zhao J, Bulek K, Li X (2019) TRAF regulation of IL-17 cytokine signaling. Front Immunol 10:1293","journal-title":"Front Immunol"},{"key":"1817_CR129","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2021-001679","volume":"7","author":"K Sweet","year":"2021","unstructured":"Sweet K, Song Q, Loza MJ, McInnes IB, Ma K, Leander K, Lakshminarayanan V, Franks C, Cooper P, Siebert S (2021) Guselkumab induces robust reduction in acute phase proteins and type 17 effector cytokines in active psoriatic arthritis: results from phase 3 trials. RMD Open 7:e001679","journal-title":"RMD Open"},{"key":"1817_CR130","doi-asserted-by":"crossref","unstructured":"Taams LS (2020) Interleukin-17 in rheumatoid arthritis: Trials and tribulations. J Exp Med 217","DOI":"10.1084\/jem.20192048"},{"key":"1817_CR131","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s41232-022-00221-x","volume":"42","author":"T Takeuchi","year":"2022","unstructured":"Takeuchi T (2022) Cytokines and cytokine receptors as targets of immune-mediated inflammatory diseases\u2014RA as a role model. Inflamm Regen 42:35","journal-title":"Inflamm Regen"},{"key":"1817_CR132","doi-asserted-by":"publisher","first-page":"1330386","DOI":"10.3389\/fimmu.2024.1330386","volume":"15","author":"A Tylutka","year":"2024","unstructured":"Tylutka A, Walas \u0141, Zembron-Lacny A (2024) Level of IL-6, TNF, and IL-1\u03b2 and age-related diseases: a systematic review and meta-analysis. Front Immunol 15:1330386","journal-title":"Front Immunol"},{"key":"1817_CR133","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.1016\/S0140-6736(16)32126-2","volume":"389","author":"R Ungaro","year":"2016","unstructured":"Ungaro R, Mehandru S, Allen PB, Peyrin-Biroulet L, Colombel J-F (2016) Ulcerative colitis. Lancet (London, England) 389:1756","journal-title":"Lancet (London, England)"},{"key":"1817_CR134","doi-asserted-by":"crossref","unstructured":"Valenti M, Gargiulo L, Ibba L, Malagoli P, Amoruso F, Balato A, Bardazzi F, Burlando M, Carrera CG, Dapavo P (2024) Long-term effectiveness and safety of ixekizumab for the treatment of moderate-to-severe plaque psoriasis: a five-year multicenter retrospective study\u2014IL PSO (Italian landscape psoriasis). Dermatol Therapy pp 1\u20139","DOI":"10.1111\/jdv.20003"},{"key":"1817_CR135","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1146\/annurev.immunol.021908.132641","volume":"27","author":"S Vallabhapurapu","year":"2009","unstructured":"Vallabhapurapu S, Karin M (2009) Regulation and function of NF-\u03baB transcription factors in the immune system. Annu Rev Immunol 27:693\u2013733","journal-title":"Annu Rev Immunol"},{"key":"1817_CR136","doi-asserted-by":"publisher","first-page":"3229","DOI":"10.3390\/biomedicines11123229","volume":"11","author":"M Vebr","year":"2023","unstructured":"Vebr M, Pomaha\u010dov\u00e1 R, S\u00fdkora J, Schwarz J (2023) A narrative review of cytokine networks: pathophysiological and therapeutic implications for inflammatory bowel disease pathogenesis. Biomedicines 11:3229","journal-title":"Biomedicines"},{"key":"1817_CR137","doi-asserted-by":"crossref","unstructured":"Wagner CA, Roqu\u00e9 PJ, Goverman JM (2020) Pathogenic T cell cytokines in multiple sclerosis. J Exp Med 217","DOI":"10.1084\/jem.20190460"},{"key":"1817_CR138","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s00415-008-1002-8","volume":"255","author":"HL Weiner","year":"2008","unstructured":"Weiner HL (2008) A shift from adaptive to innate immunity: a potential mechanism of disease progression in multiple sclerosis. J Neurol 255:3\u201311","journal-title":"J Neurol"},{"key":"1817_CR139","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/nrrheum.2015.161","volume":"12","author":"IP Wicks","year":"2016","unstructured":"Wicks IP, Roberts AW (2016) Targeting GM-CSF in inflammatory diseases. Nat Rev Rheumatol 12:37\u201348","journal-title":"Nat Rev Rheumatol"},{"key":"1817_CR140","doi-asserted-by":"publisher","first-page":"13628","DOI":"10.1038\/s41598-018-31957-7","volume":"8","author":"SK Williams","year":"2018","unstructured":"Williams SK, Fairless R, Maier O, Liermann PC, Pichi K, Fischer R, Eisel ULM, Kontermann R, Herrmann A, Weksler B, Romero N, Couraud PO, Pfizenmaier K, Diem R (2018) Anti-TNFR1 targeting in humanized mice ameliorates disease in a model of multiple sclerosis. Sci Rep 8:13628","journal-title":"Sci Rep"},{"key":"1817_CR141","doi-asserted-by":"publisher","first-page":"2041","DOI":"10.1046\/j.1532-5415.2002.50619.x","volume":"50","author":"CJ Wilson","year":"2002","unstructured":"Wilson CJ, Finch CE, Cohen HJ (2002) Cytokines and cognition\u2014the case for a head-to-toe inflammatory paradigm. J Am Geriatr Soc 50:2041\u20132056","journal-title":"J Am Geriatr Soc"},{"key":"1817_CR142","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1007\/s12026-021-09173-9","volume":"69","author":"I Wo\u015b","year":"2021","unstructured":"Wo\u015b I, Tabarkiewicz J (2021) Effect of interleukin-6,-17,-21,-22, and-23 and STAT3 on signal transduction pathways and their inhibition in autoimmune arthritis. Immunol Res 69:26\u201342","journal-title":"Immunol Res"},{"key":"1817_CR143","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1007\/s12026-024-09591-5","volume":"73","author":"Y Xiao","year":"2025","unstructured":"Xiao Y, Hong X, Neelagar R, Mo H (2025) Age-standardized incidence, prevalence, mortality rates and future projections of autoimmune diseases in China: a systematic analysis based on GBD 2021. Immunol Res 73:26","journal-title":"Immunol Res"},{"key":"1817_CR144","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1038\/cr.2008.310","volume":"18","author":"Y Xu","year":"2008","unstructured":"Xu Y, Hunt NH, Bao S (2008) The role of granulocyte macrophage-colony-stimulating factor in acute intestinal inflammation. Cell Res 18:1220\u20131229","journal-title":"Cell Res"},{"key":"1817_CR145","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1186\/s13287-022-03178-3","volume":"13","author":"C Xu","year":"2022","unstructured":"Xu C, Feng C, Huang P, Li Y, Liu R, Liu C, Han Y, Chen L, Ding Y, Shao C (2022) TNF \u03b1 and IFN \u03b3 rapidly activate PI3K-AKT signaling to drive glycolysis that confers mesenchymal stem cells enhanced anti-inflammatory property. Stem Cell Res Ther 13:491","journal-title":"Stem Cell Res Ther"},{"key":"1817_CR146","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1007\/s10620-012-2515-7","volume":"58","author":"Y Yamada","year":"2013","unstructured":"Yamada Y, Mashima H, Sakai T, Matsuhashi T, Jin M, Ohnishi H (2013) Functional roles of TGF-\u03b21 in intestinal epithelial cells through smad-dependent and non-smad pathways. Dig Dis Sci 58:1207\u20131217","journal-title":"Dig Dis Sci"},{"key":"1817_CR147","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/s13075-020-02208-w","volume":"22","author":"Y Yin","year":"2020","unstructured":"Yin Y, Wang M, Liu M, Zhou E, Ren T, Chang X, He M, Zeng K, Guo Y, Wu J (2020) Efficacy and safety of IL-17 inhibitors for the treatment of ankylosing spondylitis: a systematic review and meta-analysis. Arthritis Res Ther 22:111","journal-title":"Arthritis Res Ther"},{"key":"1817_CR148","doi-asserted-by":"publisher","first-page":"2679","DOI":"10.3389\/fimmu.2019.02679","volume":"10","author":"Y Zhan","year":"2019","unstructured":"Zhan Y, Lew AM, Chopin M (2019) The pleiotropic effects of the GM-CSF rheostat on myeloid cell differentiation and function: more than a numbers game. Front Immunol 10:2679","journal-title":"Front Immunol"},{"key":"1817_CR149","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1042\/CS20110496","volume":"122","author":"S Zhu","year":"2012","unstructured":"Zhu S, Qian Y (2012) IL-17\/IL-17 receptor system in autoimmune disease: mechanisms and therapeutic potential. Clin Sci 122:487\u2013511","journal-title":"Clin Sci"}],"container-title":["Inflammopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10787-025-01817-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10787-025-01817-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10787-025-01817-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T01:16:36Z","timestamp":1757207796000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10787-025-01817-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,28]]},"references-count":149,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["1817"],"URL":"https:\/\/doi.org\/10.1007\/s10787-025-01817-8","relation":{},"ISSN":["0925-4692","1568-5608"],"issn-type":[{"value":"0925-4692","type":"print"},{"value":"1568-5608","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,28]]},"assertion":[{"value":"11 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors certify that they have no affiliations with or involvement in any organization or entity with any financial interest (such as honoraria; educational grants; participation in speakers' bureaus; membership, employment, consultancies, stock ownership, or other equity interest; and expert testimony or patent-licensing arrangements), or non-financial interest (such as personal or professional relationships, affiliations, knowledge or beliefs) in the subject matter or materials discussed in this manuscript. The authors declare that all data were generated in-house, that no paper mill was used and that no AI tool has been used for the generation of text or figures.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}},{"value":"This article does not contain any studies with human participants performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"This is a review paper that does not require ethics approval.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human ethical approval"}},{"value":"This is a review paper that does not require consent for publication.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}